Glucose-lowering drugs that stimulate insulin secretion Glucose-lowering drugs that stimulate insulin secretion Sulfonylureas: Sulfonylureas are classified as insulin secretagogues and their primary mechanism of action is to stimulate pancreatic beta cells to secrete insulin, effectively lowering blood glucose levels
L.HnninenT.et al (1999)
The GLP-1 drugs are the latest class to show a benefit in patients, this time with OSA, but like other tools have nontrivial side effects, cost concerns, and patient persistence issues that balance out the headline benefits. The size of the underlying patient populations, which are expected to surpass 1.3 billion globally by 2050, as well as the under penetration of CPAP treatment, which Andrew ballparks at 15% or less in many markets, reinforces the analysts argument
FDA-Approved Clinical Indications Primary Indication: Prandial glucose control in Type 2 Diabetes The primary, FDA-approved use for repaglinide is the management of postprandial (post-meal) hyperglycemia in adults with Type 2 Diabetes
doi: 10.1007/s00018-019-03253-8 73 ZhangXCuiYDongLSunMZhangY